[go: up one dir, main page]

MX2017011820A - Reactivos de acilacion de aminoacidos y metodos para usar los mismos. - Google Patents

Reactivos de acilacion de aminoacidos y metodos para usar los mismos.

Info

Publication number
MX2017011820A
MX2017011820A MX2017011820A MX2017011820A MX2017011820A MX 2017011820 A MX2017011820 A MX 2017011820A MX 2017011820 A MX2017011820 A MX 2017011820A MX 2017011820 A MX2017011820 A MX 2017011820A MX 2017011820 A MX2017011820 A MX 2017011820A
Authority
MX
Mexico
Prior art keywords
amino acids
acilation
reagents
methods
same
Prior art date
Application number
MX2017011820A
Other languages
English (en)
Other versions
MX376146B (es
Inventor
Nittoli Thomas
Thirumalai Rajan Srinath
P Markotan Thomas
Jain Nareshkumar
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017011820A publication Critical patent/MX2017011820A/es
Publication of MX376146B publication Critical patent/MX376146B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

En la presente invención se proveen compuestos útiles para agregar aminoácidos a nucleófilos.
MX2017011820A 2015-03-17 2016-03-17 Reactivos de acilacion de aminoacidos y metodos para usar los mismos. MX376146B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134065P 2015-03-17 2015-03-17
PCT/US2016/022797 WO2016149464A1 (en) 2015-03-17 2016-03-17 Amino acid acylation reagents and methods of using the same

Publications (2)

Publication Number Publication Date
MX2017011820A true MX2017011820A (es) 2018-03-15
MX376146B MX376146B (es) 2025-03-07

Family

ID=55661591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011820A MX376146B (es) 2015-03-17 2016-03-17 Reactivos de acilacion de aminoacidos y metodos para usar los mismos.

Country Status (12)

Country Link
US (1) US10526344B2 (es)
EP (1) EP3271339B1 (es)
JP (1) JP6649961B2 (es)
KR (1) KR20170129769A (es)
CN (1) CN107750247A (es)
AU (1) AU2016233227B2 (es)
CA (1) CA2978182A1 (es)
EA (1) EA032630B9 (es)
IL (1) IL254205B (es)
MX (1) MX376146B (es)
SG (1) SG11201707585UA (es)
WO (1) WO2016149464A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2649458A (en) * 1951-04-30 1953-08-18 Monsanto Chemicals 2-thiono-5-oxazolidones
NL7002228A (es) 1970-02-18 1971-08-20
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4399163A (en) * 1980-11-05 1983-08-16 Pfizer Inc. Branched amides of L-aspartyl-D-amino acid dipeptides
US4946942A (en) * 1988-03-11 1990-08-07 Bioresearch, Inc. Urethane-protected amino acid-N-carboxyanhydrides
US5663333A (en) 1992-10-22 1997-09-02 The Dupont Merck Pharmaceutical Company Substituted 1,4-diazapine caprolactams useful for treatment of HIV disease
US6083950A (en) 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
PL209780B1 (pl) 2000-05-11 2011-10-31 Consejo Superior Investigacion Zastosowanie pochodnych tiadiazolidynodionu do wytwarzania leku
KR100799789B1 (ko) 2000-07-31 2008-01-31 브랜데이스 유니버시티 키랄 2- 및 3-치환된 카르복실산의 속도론적 분할
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
TWI298067B (en) 2002-01-31 2008-06-21 Daiso Co Ltd New optically active compound, method for kinetic resolution of carbonic acid derivatives and catalyst thereof
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006280146B2 (en) 2005-08-09 2012-06-28 Immunogen, Inc. Method of acylating maytansinol with chiral amino acids
NZ574619A (en) 2006-07-18 2012-03-30 Univ Rochester THIADIAZOLIDINEDIONE DERIVATIVES including 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8)
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
CN108586487B (zh) 2012-09-26 2021-11-05 伊缪诺金公司 用于美登醇酰化的改进的方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN104650113A (zh) 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN103333245B (zh) 2012-12-21 2015-03-18 百奥泰生物科技(广州)有限公司 一种针对细胞受体并抑制癌细胞生长的药物分子及其制备方法和用途
CN103333246B (zh) 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
CN104530235A (zh) 2012-12-21 2015-04-22 百奥泰生物科技(广州)有限公司 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme

Also Published As

Publication number Publication date
JP6649961B2 (ja) 2020-02-19
MX376146B (es) 2025-03-07
EA032630B1 (ru) 2019-06-28
AU2016233227B2 (en) 2020-03-12
IL254205A0 (en) 2017-10-31
US20180237456A1 (en) 2018-08-23
EP3271339B1 (en) 2021-11-24
AU2016233227A1 (en) 2017-09-14
IL254205B (en) 2019-11-28
CA2978182A1 (en) 2016-09-22
CN107750247A (zh) 2018-03-02
EA201700459A1 (ru) 2018-04-30
JP2018510157A (ja) 2018-04-12
EA032630B9 (ru) 2019-11-27
EP3271339A1 (en) 2018-01-24
US10526344B2 (en) 2020-01-07
WO2016149464A1 (en) 2016-09-22
KR20170129769A (ko) 2017-11-27
SG11201707585UA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
MX2018003491A (es) Represores de htt y usos de estos.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
DK3377206T3 (da) Medieblandekammer
HUE058802T2 (hu) RIPK1 inhibitorokként alkalmas vegyületek
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CR20160444A (es) Proteínas de fusión uti
EP3479227A4 (en) CORRELATION OF MULTIPLE SOURCES
CO2017010143A2 (es) Procesos para preparar fluorocetólidos

Legal Events

Date Code Title Description
FG Grant or registration